Literature DB >> 10705201

Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation.

H Matsuura1, N Hayashi, J Kawamura, T Shiraishi, R Yatani.   

Abstract

OBJECTIVE: This study was performed to examine the expressions of Ki-67 antigen, bcl-2 and p53 oncoprotein and to assess their capacity to predict the short-term response to the initial endocrine treatment and disease progression in prostate cancer.
METHODS: Formalin-fixed and paraffin-embedded tumor tissues from a total of 73 patients with untreated prostate cancers were collected by transrectal ultrasound-guided biopsy. All patients with stage C or D prostate cancers had received continuous endocrine treatment. Ki-67 antigen, p53 and bcl-2 oncoprotein were detected by immunohistochemical methods.
RESULTS: Short-term response to initial endocrine therapy judged at 3 months showed a significant correlation with Ki-67 labeling index (LI) and bcl-2 expression. Multivariate analysis showed that only a high Ki-67 LI was an independent potential predictor of prostate-specific antigen failure or the appearance of new metastasis.
CONCLUSIONS: The findings suggested that the Ki-67 LI was the most useful parameter to predict disease progression after the initial endocrine treatment. Additional studies must be performed to evaluate the prognostic significance of both cell proliferation and apoptosis in detail.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705201     DOI: 10.1159/000020120

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

Authors:  Li-Yan Khor; Michelle Desilvio; Rile Li; Timothy J McDonnell; M Elizabeth H Hammond; William T Sause; Miljenko V Pilepich; Paul Okunieff; Howard M Sandler; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-11       Impact factor: 7.038

2.  Evaluation of PSF1 as a prognostic biomarker for prostate cancer.

Authors:  H Tahara; H Naito; K Kise; T Wakabayashi; K Kamoi; K Okihara; A Yanagisawa; Y Nakai; N Nonomura; E Morii; T Miki; N Takakura
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-18       Impact factor: 5.554

Review 3.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.